title: Androgen deprivation in prostate cancer and the long-term risk of fracture.
abstract: OBJECTIVE
  To determine the rate of bone mass loss and the risk of fracture induced by androgen deprivation therapy in patients with prostate cancer.
  
  
  METHODS
  Prospective study in 2 phases. In the first phase, demographic variables, FRAX®, bone mineral density and clinical fractures were collected, before starting the therapy and up to 1 year after ending the therapy. In the second phase, we conducted a telephone interview a mean of 8.5 years after the start of the study to assess new fractures.
  
  
  RESULTS
  We included 150 patients with a mean age of 67 years and a mean therapy duration of 24 months. Before starting the treatment, 62 patients (41%) showed osteoporosis or low bone mass in the densitometry. After the first year of treatment, the bone mineral density decreased a mean of 3.7% and 2.1% in the lumbar spine and femoral neck, respectively. At the end of the second and third year, the loss rate was lower. During the first phase of the study, 4 patients (2.7%) experienced a fracture. In the telephone interviews with 80 patients (53%), only 1 had experienced a fracture.
  
  
  CONCLUSIONS
  In the patients with prostate cancer and androgen deprivation therapy, greater bone loss occurred during the first year. When the treatment did not exceed 2 years, the absolute risk of fracture was low, and clinical fractures were uncommon in the short and long term.
authors.affiliation: Servicio de Reumatología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, España. Electronic address: soas@medicoslaspalmas.es.
authors.forename: S
authors.initials: S
authors.lastname: Ojeda
authors.affiliation: Servicio de Oncología Radioterápica, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, España.
authors.forename: M
authors.initials: M
authors.lastname: Lloret
authors.affiliation: Servicio de Reumatología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, España.
authors.forename: A
authors.initials: A
authors.lastname: Naranjo
authors.affiliation: Servicio de Urología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, España.
authors.forename: F
authors.initials: F
authors.lastname: Déniz
authors.affiliation: Servicio de Urología, Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria, Las Palmas de Gran Canaria, España.
authors.forename: N
authors.initials: N
authors.lastname: Chesa
authors.affiliation: Servicio de Análisis Clínico, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, España.
authors.forename: C
authors.initials: C
authors.lastname: Domínguez
authors.affiliation: Servicio de Oncología Radioterápica, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, España.
authors.forename: P C
authors.initials: PC
authors.lastname: Lara
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy; D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000728:Androgens / Q000502:physiology; D000813:Anilides / Q000009:adverse effects* / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005272:Femur Neck / Q000000981:diagnostic imaging; D005500:Follow-Up Studies; D005598:Fractures, Spontaneous / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D006801:Humans; D007407:Interviews as Topic; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000150:complications / Q000188:drug therapy*; D009570:Nitriles / Q000009:adverse effects* / Q000627:therapeutic use; D010024:Osteoporosis / Q000139:chemically induced* / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy; D018570:Risk Assessment; D012984:Software; D014105:Tosyl Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D014807:Vitamin D / Q000627:therapeutic use
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D000813:Anilides; D018931:Antineoplastic Agents, Hormonal; D050071:Bone Density Conservation Agents; D009570:Nitriles; D014105:Tosyl Compounds; D014807:Vitamin D; D007987:Gonadotropin-Releasing Hormone; C053541:bicalutamide; D002118:Calcium
keywords: Androgen deprivation therapy; Bisfosfonatos; Bisphosphonates; Cáncer de próstata; Fractura; Fracture; Osteoporosis; Prostate cancer; Terapia de deprivación androgénica